Publisher
Springer Science and Business Media LLC
Reference15 articles.
1. Foulks GN. DEWS report: a mission completed. Ocul Surf. 2007;5(2):65–6.
2. Anonymous: Ophthalmic drug products for over-the-counter human use; final monograph. Fed Reg 1988;53(43):7076-7093.
3. Novack GD. Pipeline: how are tear lubricant products regulated in the US? Ocul Surf. 2003;1(2):86.
4. • Pflugfelder SC, Geerling G, Kinoshita S, Lemp MA, McCulley J, Nelson D, Novack GD, Shimazaki J, Wilson C: Management and therapy of dry eye disease: Report of the Management and Therapy Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf 2007;5(2):163-178. This part of the Dry Eye Workshop (DEWS) report gives then current consensus on disease management and therapy.
5. • Sullivan DA, Hammitt KM, Schaumberg DA, Sullivan BD, Begley CB, Gjorstrup P, Garrigue J-S, Nakamura M, Quentric Y, Barabino S, Dalton M, Novack GD: Report of the TFOS/ARVO symposium on global treatments for dry eye disease: an unmet need. Ocul Surf 2012;10(2):108–116. These proceedings of a regulatory symposium held just prior to the TFOS meeting in 2010 give a good view of the current worldwide regulatory status of novel pharmacological therapies.